Publication:
Trefoil Factor 3 Expression in Immunoglobulin A Nephropathy.

No Thumbnail Available

Date

2014-11-11

Journal Title

Journal ISSN

Volume Title

Publisher

Research Projects

Organizational Units

Journal Issue

Abstract

Background: Peritoneal fl uid of PD patients includes various substances. Trefoil Factor 3 (TFF3) is secreted from different kinds of epithelial cells. It increases survival of epithelial cells and facilitates the restoration of cells aganist any kind of injury. TFF3 levels in the effl uent and serum of PD patients were measured and associated factors were investigated. Effl uent CA-125 levels which is known as indicator of mesothelial cell mass were ascertained for the potential association. Methods: Peritoneal fl uid and serum samples of 48 patients were collected after a 12 hour dwell. ELISA kit (BioTek Instruments U.S.A.) was used for the detection of TFF3 levels. The patients’ demographic and laboratory data as well as peritoneal membrane characteristics were recorded. Results: Fourty-eight PD patients (24 men; mean age: 51,6 ± 13,9 years) who have a median treatment time of 43 months (range:3-200 months) were included. Median effl uent TFF3 level was 17,07 ng/ml (range: 2,38-99,4 ng/ml). There was a positive correlation between effl uent TFF3 levels and treatment time (r=0,349, p<0,015). Median serum TFF3 level was 1,56 ng/ml (range: 0,79-11,05ng/ml). There was no statistical association between effl uent and serum TFF3 levels and effl uent CA-125 levels. There was no statistical association with demographic features, labarotary results and treatment modalities except serum PTH levels (p<0,05). Conclusions: High serum TFF3 levels were comparable with other studies including patients with chronic kidney disease. Effl uent TFF3 levels increases with treatment time may be emanated from local production or peritoneal transport. Tissue localization of TFF3 in peritoneal microcirculation, determination of peritoneal clearance of TFF3 and indicating the association with pro-infl amatory cytokines could make TFF3 possible to be used as a biomarker in PD patients.

Description

Keywords

Citation

GÜLER D., ARIKAN İ. H., BARUTÇU ATAŞ D., AŞICIOĞLU E., VELİOĞLU A., KOÇ M., TUĞLULAR Z. S., ÖZENER İ. Ç., \"Trefoil Factor 3 Expression in Immunoglobulin A Nephropathy.\", ASN Kidney Week 2014, Philadelphia, PA, Nov 11-16 2014, 11 - 16 Kasım 2014, cilt.25, ss.956

Collections